Nintedanib is an inhibitor of multiple tyrosine kinases including vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF) and fibroblast growth factor (FGF) (33), which is approved for the treatment of progressive fibrosing interstitial lung diseases (PF-ILD) (34) in March, 2020. The gene discussed is VEGFA; the disease is pemphigus foliaceus.